Ceftazidime with avibactam

UK SPC (Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion), adults with estimated creatinine clearance greater than 50 mL/min. The same 2 g/0.5 g every 8 hours over 2 hours applies to every licensed indication; only the duration differs — complicated intra-abdominal infection (cIAI) 5 to 14 days; complicated urinary tract infection including pyelonephritis (cUTI) 5 to 10 days (the total duration shown may include intravenous therapy followed by appropriate oral therapy); hospital-acquired pneumonia including ventilator-associated pneumonia (HAP/VAP) 7 to 14 days; bacteraemia associated with, or suspected to be associated with, any of these infections — duration in accordance with the site of infection; infections due to aerobic Gram-negative organisms in patients with limited treatment options — duration guided by the severity of the infection, the pathogen(s) and the patient's clinical and bacteriological progress. There is very limited experience with use for more than 14 days. COMBINATION USE: to be used with metronidazole when anaerobic pathogens are known or suspected to be contributing, and with an agent active against Gram-positive pathogens when these are known or suspected to be contributing. It is recommended that Zavicefta be used to treat infections due to aerobic Gram-negative organisms in adults and paediatric patients from birth with limited treatment options only after consultation with a physician experienced in the management of infectious diseases. ELDERLY: no dosage adjustment required.

dosePerKg refers to the CEFTAZIDIME component — ceftazidime/avibactam is a fixed 4:1 combination and the SPC's dose recommendations are based on the ceftazidime component only; the matching avibactam dose is 12.5 mg/kg. UK SPC, paediatric patients with estimated CrCl greater than 50 mL/min/1.73 m2 (Schwartz bedside formula): 6 months to less than 18 years — 50 mg/kg / 12.5 mg/kg to a maximum of 2 g/0.5 g every 8 hours over 2 hours; 3 months to less than 6 months — 40 mg/kg / 10 mg/kg every 8 hours (limited experience). Less than 3 months (patients with serum creatinine at or below the upper limit of normal for age): full-term neonates and infants over 28 days to less than 3 months — 30 mg/kg / 7.5 mg/kg every 8 hours; birth to 28 days or less — 20 mg/kg / 5 mg/kg every 8 hours; preterm infants (less than 37 weeks gestation) over 44 to less than 53 weeks postmenstrual age — 30 mg/kg / 7.5 mg/kg every 8 hours; 31 to 44 weeks or less postmenstrual age — 20 mg/kg / 5 mg/kg every 8 hours; 26 to less than 31 weeks postmenstrual age — 20 mg/kg / 5 mg/kg every 12 hours (this band is based on pharmacokinetic modelling only). Durations as for adults (cIAI 5-14 days, cUTI 5-14 days, HAP/VAP 7-14 days). Patients studied from 3 to 12 months of age were full term (37 weeks gestation or more). Verify the paediatric regimen against a children's formulary before use.